Prof Ken Kato speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about the results from the KEYNOTE-590 trial.
The phase III study looked at pembrolizumab plus chemotherapy vs chemotherapy alone as first-line therapy in patients with advanced oesophageal cancer.
Prof Kato reports that the addition of pembrolizumab showed superior overall survival, progression free survival and overall response-rate in these patients.
See related news here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.